Stocktoria
Aclarion, Inc. ACON
Nasdaq · XNAS · stock · Services-Medical Laboratories · website · IPO 2022-04-22
Aclarion, Inc. financials (annual, from 10-K)
| Metric | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 |
|---|---|---|---|---|---|
| Revenue | $75,730 | $45,724 | $75,404 | $60,444 | $60,292 |
| Gross profit | $6,828 | -$38,934 | -$324 | -$4,854 | -$8,883 |
| R&D expense | $1.0M | $888,766 | $873,336 | $1.1M | $787,850 |
| Operating income | -$7.1M | -$5.5M | -$4.9M | -$5.6M | -$3.0M |
| Interest expense | — | $64,084 | $110,525 | $1.5M | $474,911 |
| Income tax | $0 | $0 | $0 | $0 | $0 |
| Net income | -$7.2M | -$7.0M | -$4.9M | -$7.1M | -$5.0M |
| EPS (diluted) | $-13.61 | $-7478.90 | $-79782.00 | $-19.61 | $-6.58 |
| Operating cash flow | -$7.2M | -$5.3M | -$3.6M | -$4.9M | -$2.4M |
| Free cash flow | -$7.2M | -$5.3M | -$3.6M | — | — |
| Cash & equivalents | $12.0M | $453,661 | $1.0M | $1.5M | $432,530 |
| Total assets | $13.7M | $2.1M | $2.5M | $2.9M | $1.9M |
| Total liabilities | $837,287 | $1.2M | $3.2M | — | $7.6M |
| Shareholders' equity | $12.8M | $970,057 | -$727,995 | $2.2M | -$12.8M |
Source: SEC EDGAR filings · CIK 0001635077 · as of 2025-12-31. Facts from filings plus Stocktoria's own computed scores — not investment advice.